DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract 
Eckert & Ziegler: Affiliates Receives Additional NIAID Funding to Advance Pharmaceutical Development 
2021-06-08 / 09:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Berlin, 8 June 2021 - Myelo Therapeutics GmbH, an affiliate of Eckert & Ziegler (ISIN DE0005659700, TecDAX) focused on 
developing medical countermeasures (MCM) and therapies for cancer supportive care, announced that the U.S. National 
Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, extended their 
contract to advance the development of the new chemical entity Myelo001. The extension into year two of the three-year 
contract provides an additional USD2 million to Myelo Therapeutics to develop clinical-stage Myelo001 as an oral 
formulation MCM for the treatment of Hematopoietic Acute Radiation Syndrome (H-ARS). The total contract, initially 
awarded in April 2020, is valued at up to USD 6.2 million over three years if all options are exercised. 
The additional funds will advance the development of Myelo001 as an H-ARS monotherapy, and in polypharmacy regimens in 
laboratory models ranging from rodents to larger animals toward an Investigational New Drug Application (IND) with the 
U.S. Food and Drug Administration (FDA). The candidate MCM development program is funded in whole or in part by the 
Radiation and Nuclear Countermeasures Program (RNCP), NIAID, part of the National Institutes of Health (NIH), in the 
Department of Health, and Human Services (HHS), under Contract No. 75N93020C00005. Only a select number of companies 
are funded by the RNCP, based on a highly competitive application process. 
About Acute Radiation Syndrome 
ARS, also known as radiation toxicity or radiation sickness, is an acute illness that presents after exposure of large 
portions of the body to high levels of radiation, like those that might be experienced during a radiological or nuclear 
incident. The primary manifestation of ARS is the depletion of hematopoietic stem and progenitor cells, constituting 
one of the major causes of mortality. The U.S. government encourages development of new drugs to treat bodily injuries 
resulting from ARS. 
About Myelo Therapeutics 
Myelo Therapeutics is a pharmaceutical company based in Berlin, Germany, that is developing innovative treatments in 
areas of high unmet medical needs, such as Chemotherapy-Induced Myelosuppression (CIM), Radiation-Induced 
Myelosuppression (RIM), and ARS. Myelo's lead candidate, Myelo001 is a clinical-stage, adjuvant cancer therapy for 
treatment of chemotherapy - and radiotherapy-induced myelosuppression. It is delivered as an oral tablet formulation 
and is stable at room temperature for at least three years. Preclinical and clinical studies have shown that Myelo001 
has both prophylactic and therapeutic efficacy at reducing hematopoietic symptoms caused by radiation and chemotherapy. 
Eckert & Ziegler is one of Myelo's largest shareholder and has funded a substantial portion of the Myelo001 development 
activities. www.myelotherapeutics.com. 
About Eckert & Ziegler. 
Eckert & Ziegler Strahlen- und Medizintechnik AG with her 800 employees is a leading specialist for isotope-related 
components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the 
radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler 
shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. 
Contributing to saving lives. 
Your contact: 
Eckert & Ziegler AG, Karolin Riehle, Investor Relations 
Robert-Rössle-Str. 10, 13125 Berlin, Germany 
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-08 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Eckert & Ziegler Strahlen- und Medizintechnik AG 
              Robert-Rössle-Str.10 
              13125 Berlin 
              Germany 
Phone:        +49 30 941084-138 
Fax:          +49 30 941084-112 
E-mail:       karolin.riehle@ezag.de 
Internet:     www.ezag.de 
ISIN:         DE0005659700 
WKN:          565970 
Indices:      SDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1205436 
 
End of News   DGAP News Service 
=------------

1205436 2021-06-08


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1205436&application_name=news

(END) Dow Jones Newswires

June 08, 2021 03:31 ET (07:31 GMT)